

Table 14.10
De Novo Posttransplant Solid Malignancy, 1998 to 2007
Heart Recipients

	Year of Transplant									
	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007
Total # of Post-Tx Malignancies	554	431	424	326	246	179	131	122	50	6
Malignancies by Type										
Squamous/Basal Cell Carcinoma	317	246	231	196	135	112	70	71	36	2
Melanoma	21	20	16	12	7	12	8	2	2	1
Kaposi Sarcoma	3	1	-	1	-	-	-	-	1	-
Central Nervous System	6	5	3	-	-	-	-	1	1	-
Genito-Urinary (1)	73	64	61	42	31	19	24	16	4	-
Gastro-Intestinal (2)	16	16	25	13	14	11	3	6	2	-
Primary Hepatic Tumor	2	1	2	2	-	-	-	-	-	-
Metastatic Hepatic Tumor	5	5	4	2	5	4	1	1	-	-
Larynx/Bronchi/Lung	61	51	41	33	27	9	13	11	2	1
Breast/Thyroid	18	9	8	12	4	6	5	3	-	1
Leukemia	3	2	-	-	5	-	-	1	-	-
Sarcoma (3)	1	-	2	-	4	-	-	-	-	-
Other	23	9	27	12	13	4	6	10	1	1
Unknown	5	2	4	1	1	2	1	-	1	-
Malignancies by Type (%)										
Squamous/Basal Cell Carcinoma	57.2%	57.1%	54.5%	60.1%	54.9%	62.6%	53.4%	58.2%	72.0%	33.3%
Melanoma	3.8%	4.6%	3.8%	3.7%	2.8%	6.7%	6.1%	1.6%	4.0%	16.7%
Kaposi Sarcoma	0.5%	0.2%	-	0.3%	-	-	-	-	2.0%	-
Central Nervous System	1.1%	1.2%	0.7%	-	-	-	-	0.8%	2.0%	-
Genito-Urinary (1)	13.2%	14.8%	14.4%	12.9%	12.6%	10.6%	18.3%	13.1%	8.0%	-
Gastro-Intestinal (2)	2.9%	3.7%	5.9%	4.0%	5.7%	6.1%	2.3%	4.9%	4.0%	-
Primary Hepatic Tumor	0.4%	0.2%	0.5%	0.6%	-	-	-	-	-	-
Metastatic Hepatic Tumor	0.9%	1.2%	0.9%	0.6%	2.0%	2.2%	0.8%	0.8%	-	-
Larynx/Bronchi/Lung	11.0%	11.8%	9.7%	10.1%	11.0%	5.0%	9.9%	9.0%	4.0%	16.7%
Breast/Thyroid	3.2%	2.1%	1.9%	3.7%	1.6%	3.4%	3.8%	2.5%	-	16.7%
Leukemia	0.5%	0.5%	-	-	2.0%	-	-	0.8%	-	-
Sarcoma (3)	0.2%	-	0.5%	-	1.6%	-	-	-	-	-
Other	4.2%	2.1%	6.4%	3.7%	5.3%	2.2%	4.6%	8.2%	2.0%	16.7%
Unknown	0.9%	0.5%	0.9%	0.3%	0.4%	1.1%	0.8%	-	2.0%	-
Total # of Patients	331	277	260	212	168	122	103	86	40	5

Source: OPTN/SRTR Data as of May 1, 2008.

Notes:

(-) = None in category.

(1) Genito-Urinary: kidney, bladder, uterine cervix, uterine body, ovarian, vulva, testicular, prostate.

(2) Gastro-Intestinal: tongue, throat, esophagus, stomach, small intestine, colo-rectal, liver and biliary tract, pancreas.

(3) Sarcoma: fibrosarcoma, osteosarcoma, etc.

Recipient malignancy statistics are based on voluntary reporting to the OPTN.